ENGLEWOOD, Colo. , Aug. 3, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has the company's Founder and CEO, Thomas Sandgaard will participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar at 12:15 PM ET on August 3rd, 2023.
Commenting on the upcoming webinar, Thomas Sandgaard, CEO and Founder of Zynex, said, "I'm looking forward to speaking to investors at today's event. Benzinga provides a good venue to inform new investors of the strong earnings Zynex continues to deliver."
The webinar will be broadcast live on Youtube beginning at 11:00 AM ET. Interested investors can use the following link to view and post questions to management:
About Benzinga
Benzinga helps you build wealth. The financial world is difficult to understand, noisy and scary. Wall Street professionals get all the shortcuts and everyday people have to walk the long way. So Benzinga shepherds you through personal finance, investing, trading and every other way to grow wealth. You can find our news wherever you trade — TD Ameritrade, Robinhood, WeBull, and more. Our mission is to connect the world with news, data and education that makes the path to financial prosperity easier for everyone, everyday. Benzinga was launched in 2010 by founder Jason Raznick. Today the company is headquartered in Detroit, Michigan.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Contact
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$2.51 |
Daily Change: | 0.11 4.58 |
Daily Volume: | 244,521 |
Market Cap: | US$79.940M |
June 30, 2025 April 29, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load